[go: up one dir, main page]

AR083200A1 - Compuestos de n-heteroarilo - Google Patents

Compuestos de n-heteroarilo

Info

Publication number
AR083200A1
AR083200A1 ARP110103573A ARP110103573A AR083200A1 AR 083200 A1 AR083200 A1 AR 083200A1 AR P110103573 A ARP110103573 A AR P110103573A AR P110103573 A ARP110103573 A AR P110103573A AR 083200 A1 AR083200 A1 AR 083200A1
Authority
AR
Argentina
Prior art keywords
alkyl
aminocarbonyl
hydrogen
cycloalkyl
amino
Prior art date
Application number
ARP110103573A
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR083200A1 publication Critical patent/AR083200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El medicamento puede usarse preferiblemente para tratar infecciones helmínticas y el tratamiento de parasitosis, tales como las provocadas por infecciones helmínticas. También se refiere a usos de los compuestos para elaborar medicamentos y tratamientos que comprenden la administración de los compuestos a animales que necesitan dichos tratamientos. También se refiere a compuestos de N-heteroarilo y a la preparación de dichos compuestos y a composiciones farmacéuticas y kits que comprenden los compuestos.Reivindicación 1: Un compuesto de la fórmula (1) y sus sales, solvatos, N-óxidos o profármacos farmacéuticamente aceptables, donde R1 es halógeno, alquilo C1-6, alquiloxi C1-6, alquiltio C1-6, alquenilo C2-6, alquinilo C2-6, alquiloxi C1-6-alquilo C1-6, alquiltio C1-6-alquilo C1-6, alquilo C1-6-carbonilo, alquenilo C2-6-carbonilo, SF5, alquilo C1-6-sulfonilo donde cada uno de los radicales que contienen carbonos opcionalmente está sustituido con uno o varios átomos de halógeno, preferiblemente átomos de flúor; R2 es hidrógeno, halógeno, alquilo C1-6, alquiloxi C1-6, alquiltio C1-6, alquenilo C2-6, alquinilo C2-6, alquiloxi C1-6- alquilo C1-6, alquiltio C1-6-alquilo C1-6, alquilo C1-6-carbonilo, alquenilo C2-6-carbonilo, alquenilo C2-6-carbonilo, donde cada uno de los radicales que contienen carbonos opcionalmente está sustituido con uno o varios átomos de halógeno, preferiblemente átomos de flúor; R3 es hidrógeno, alquilo C1-6 o cicloalquilo, preferiblemente hidrógeno; R4 es hidrógeno, alquilo C1-6 o cicloalquilo, preferiblemente hidrógeno; R5 es hidrógeno, alquilo C1-6, cicloalquilo, acilo, cicloalquiloxicarbonilo, alquiloxi C1-6-carbonilo; R6 es hidrógeno, alquilo C1-6, cicloalquilo, hidroxi, alquiloxi C1-6, fenil-alquiloxi C1-6, hidroxi-alquilo C1-6, alquiloxi C1-6-alquilo C1-6, fenil-alquiloxi C1-6-alquilo C1-6, tiol-alquilo C1-6, alquiltio C1-6-alquilo C1-6, fenil-alquiltio C1-6-alquilo C1-6, hidroxicarbonilo, hidroxicarbonil-alquilo C1-6, alquiloxi C1-6-carbonilo, alquiloxi C1-6-carbonil-alquilo C1-6, aminocarbonilo, aminocarbonil-alquilo C1-6, alquilo C1-6-aminocarbonilo, alquilo C1-6-aminocarbonilo-alquilo C1-6, di(alquilo C1-6)aminocarbonilo, di(alquilo C1-6)aminocarbonilo-alquilo C1-6, alquilo C1-6-amino-alquilo C1-6, di(alquilo C1-6)amino-alquilo C1-6, fenilo, fenil-alquilo C1-6, donde cada grupo fenilo está opcionalmente sustituido con hidroxi, cicloalquiloxi o alquiloxi C1-6; R7 es hidrógeno, alquilo C1-6 o cicloalquilo; o R6 está unido a R8 para formar un grupo alquileno C1-3 y R7 está unido a R9 para formar un grupo alquileno C1-3, donde uno o ambos de dichos grupos alquileno C1-3 están opcionalmente sustituidos con uno o varios radicales alquilo C1-6 o cicloalquilo; n es un número entero de 1 a 3; X es un grupo carbonilo, tiocarbonilo o sulfonilo, preferiblemente un grupo carbonilo; A es un enlace o NR8, donde R8 es hidrógeno o alquilo C1-6, preferiblemente hidrógeno; E es un enlace o NR9, donde R9 es hidrógeno o alquilo C1-6, preferiblemente hidrógeno; B es N o CR10, donde R10 es hidrógeno o alquilo C1-6, preferiblemente hidrógeno; D es N o CR11, donde R11 es hidrógeno o alquilo C1-6, preferiblemente hidrógeno; Y1 es C o N, donde C está sustituido con R12 que es hidrógeno, halógeno, alquilo C1-6, alquenilo C1-6, cicloalquilo, cicloalquiloxi, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitrilo, nitro, amino, alquilo C1-6-amino, cicloalquilamino, di(alquilo C1-6)amino, (alquilo C1-6)-(cicloalquil)amino, N-pirrolidinilo, N-piperidinilo, N-morfolinilo, alquiltio C1-6, cicloalquiltio, haloalquiltio C1-6, alquilo C1-6-carbonilo, haloalquilo C1-6-carbonilo, alquilo C1-6-carbonilamino, aminocarbonilo, alquilo C1-6-aminocarbonilo, di(alquilo C1-6)-aminocarbonilo, alcoxi C1-6-carbonilo, fenilo, dioxolano tal como 1,3-dioxolano, dioxano tal como 1,3-dioxano, o dioxepano tal como 1,3-dioxepano, cada uno de dichos anillos no está sustituido o está sustituido con alquilo C1-6; Y2 es C o N, donde C está sustituido con R13 que es hidrógeno, halógeno, alquilo C1-6, alquenilo C1-6, cicloalquilo, cicloalquiloxi, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitrilo, nitro, amino, alquilo C1-6-amino, cicloalquilamino, di(alquilo C1-6)amino, (alquilo C1-6)-(cicloalquil)amino, N-pirrolidinilo, N-piperidinilo, N-morfolinilo, tiol, hidroxi, alquiltio C1-6, cicloalquiltio, haloalquiltio C1-6, alquilo C1-6-carbonilo, haloalquilo C1-6-carbonilo, aminocarbonilo, alquilo C1-6-aminocarbonilo, di(alquilo C1-6)-aminocarbonilo, alquilo C1-6-carbonilamino, alcoxi C1-6-carbonilo, dioxolano tal como 1,3-dioxolano, dioxano tal como 1,3-dioxano, o dioxepano tal como 1,3-dioxepano, cada uno de dichos anillos no está sustituido o está sustituido con alquilo C1-6; Y3 es C o N, donde C está sustituido con R14 que es hidrógeno, halógeno, alquilo C1-6, alquenilo C1-6, cicloalquilo, cicloalquiloxi, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitrilo, nitro, amino, alquilo C1-6-amino, cicloalquilamino, di(alquilo C1-6)amino, (alquilo C1-6)-(cicloalquil)amino, N-pirrolidinilo, N-piperidinilo, N-morfolinilo, tiol, hidroxi, alquiltio C1-6, cicloalquiltio, haloalquiltio C1-6, alquilo C1-6-carbonilo, haloalquilo C1-6-carbonilo, alquilo C1-6-carbonilamino, aminocarbonilo, alquilo C1-6-aminocarbonilo, di(alquilo C1-6)aminocarbonilo, alcoxi C1-6-carbonilo, dioxolano tal como 1,3-dioxolano, dioxano tal como 1,3-dioxano, o dioxepano tal como 1,3-dioxepano, cada uno de dichos anillos no está sustituido o está sustituido con alquilo C1-6; Y4 es C o N, donde C está sustituido con R15 que es hidrógeno, halógeno, alquilo C1-6, alquenilo C1-6, cicloalquilo, cicloalquiloxi, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitrilo, nitro, amino, alquilo C1-6-amino, cicloalquilamino, di(alquilo C1-6)amino, (alquilo C1-6)-(cicloalquil)amino, N-pirrolidinilo, N-piperidinilo, N-morfolinilo, alquiltio C1-6, haloalquiltio C1-6, alquilo C1-6-carbonilo, haloalquilo C1-6-carbonilo, alquilo C1-6-carbonilamino, aminocarbonilo, alquilo C1-6-aminocarbonilo, di(alquilo C1-6)aminocarbonilo, alcoxi C1-6-carbonilo, fenilo, dioxolano tal como 1,3-dioxolano, dioxano tal como 1,3-dioxano, o dioxepano tal como 1,3-dioxepano, cada uno de dichos anillos no está sustituido o está sustituido con alquilo C1-6; o Y1 e Y2 y/o Y3 e Y4 se unen entre sí para formar un sistema de anillos, y donde por lo menos uno de B y D es un átomo de nitrógeno.
ARP110103573A 2010-09-29 2011-09-28 Compuestos de n-heteroarilo AR083200A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10181553 2010-09-29
US38846610P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
AR083200A1 true AR083200A1 (es) 2013-02-06

Family

ID=44719930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103573A AR083200A1 (es) 2010-09-29 2011-09-28 Compuestos de n-heteroarilo

Country Status (17)

Country Link
US (1) US8877934B2 (es)
EP (1) EP2621903B1 (es)
JP (1) JP5791725B2 (es)
KR (1) KR101916481B1 (es)
CN (2) CN103189356B (es)
AR (1) AR083200A1 (es)
AU (1) AU2011310592B2 (es)
BR (1) BR112013006030B1 (es)
CA (1) CA2811369C (es)
CO (1) CO6710926A2 (es)
ES (1) ES2622881T3 (es)
HU (1) HUE034042T2 (es)
MX (1) MX340985B (es)
NZ (1) NZ607580A (es)
PL (1) PL2621903T3 (es)
RU (1) RU2596185C2 (es)
WO (1) WO2012041873A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842144B2 (en) * 2011-05-13 2020-11-24 The Climate Corporation Method and system to map biological pests in agricultural fields using remotely-sensed data for field scouting and targeted chemical application
US10096073B2 (en) 2011-05-13 2018-10-09 The Climate Corporation Systems to prescribe and deliver fertilizer over agricultural fields and related methods
EP2831042B1 (en) * 2012-03-28 2019-07-31 Intervet International B.V. Heteroaryl compounds with a-cyclic bridging unit
NZ708681A (en) * 2012-12-13 2016-09-30 Dow Agrosciences Llc Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates
BR102013032003A2 (pt) * 2012-12-13 2014-10-21 Dow Agrosciences Llc Processo para a preparação de 4-amino-5-fluoro-3-cloro-6-(substituído)picolinato
EP3145904A1 (en) 2014-05-21 2017-03-29 Intervet International B.V. Improved process for preparing substituted crotonic acids
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2016378477A1 (en) * 2015-12-23 2018-06-14 Intervet International B.V. Improved process for making crotonylaminopyridines
AR111260A1 (es) 2017-03-31 2019-06-19 Intervet Int Bv Formulación farmacéutica de la sal de crotonil amino piridina
JP7292394B2 (ja) 2018-12-21 2023-06-16 サルティゴ・ゲーエムベーハー ２－アルコキシ－４－アミノ－５－メチル－ピリジン及び／又は２－アルコキシ－４－アルキルアミノ－５－メチル－ピリジンを調製するためのプロセス
CN114846014B (zh) 2019-12-18 2025-06-13 英特维特国际股份有限公司 包含氮杂吲哚结构的驱虫化合物
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
CN110960485B (zh) * 2020-01-06 2021-02-02 安丘市人民医院 一种用于治疗角膜炎的药物及其制备方法
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2025152919A1 (en) * 2024-01-15 2025-07-24 Impact Therapeutics (Shanghai) , Inc. Crystal forms of a weel inhibitor and preparation method thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2709094C2 (de) * 1977-03-02 1984-11-22 Boehringer Mannheim Gmbh, 6800 Mannheim Adsorbens für die affinitätsspezifische Trennung von Nukleinsäuren, Verfahren zu seiner Herstellung und seine Verwendung
CA1131225A (en) * 1977-03-02 1982-09-07 Werner Muller Dyestuffs as affine residues
DE2758036A1 (de) * 1977-12-24 1979-07-05 Boehringer Mannheim Gmbh Adsorbens fuer die affinitaetsspezifische trennung von makromolekularen stoffen, verfahren zu seiner herstellung und seine verwendung
US5098462A (en) 1985-08-20 1992-03-24 Sandoz Ltd. Substituted semi-carbazones and related compounds
EP0539588A1 (en) 1990-07-05 1993-05-05 Nippon Soda Co., Ltd. Amine derivative
JP2986187B2 (ja) * 1990-08-31 1999-12-06 コニカ株式会社 感熱転写材料による画像形成方法
FR2683817B1 (fr) * 1991-11-18 1994-02-25 Upsa Laboratoires Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
JP3020279B2 (ja) 1995-03-20 2000-03-15 メルク エンド カンパニー インコーポレーテッド ノジュリスポル酸誘導体
US5595991A (en) 1995-03-20 1997-01-21 Merck & Co., Inc. Anthelmintic use of nodulisporic acid and analogs thereof
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
WO1997029079A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) * 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US5834260A (en) 1996-08-30 1998-11-10 Merck & Co., Inc. Antiparasitic agents
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP1465889B1 (en) * 2001-12-21 2017-03-22 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TW200418863A (en) * 2002-10-17 2004-10-01 Upjohn Co Novel anthelmintic and insecticidal compositions
KR100470076B1 (ko) 2002-11-27 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JPWO2004052871A1 (ja) 2002-12-06 2006-04-13 東レ株式会社 ベンゾモルホリン誘導体
WO2005066119A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Antibacterial 1-(4-mono-and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoropropanols and preparation thereof
KR20060110344A (ko) 2003-12-31 2006-10-24 쉐링-프라우 리미티드 이미다조[1,2-ｂ]피리다진 유도체를 사용하여 동물에서기생충을 방제하는 방법
AU2005219788B2 (en) 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
WO2006010084A2 (en) * 2004-07-06 2006-01-26 Segev Laboratories Limited A system for delivering therapeutic agents into living cells and cell nuclei
PE20060693A1 (es) 2004-09-23 2006-09-01 Schering Plough Ltd Nuevos derivados de trifluorometansulfonanilida oxamida eter
ATE446677T1 (de) 2004-11-19 2009-11-15 Schering Plough Ltd Kontrolle von parasiten bei tieren mittels verwendung von parasitiziden 2-phenyl-3-(1h- pyrrol-2-yl) acrylonitril-derivaten
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
CN101175729B (zh) * 2004-12-07 2011-06-01 梅瑞尔有限公司 1-苯基-3-哌嗪-吡唑及其杀虫组合物
US20060147847A1 (en) * 2004-12-30 2006-07-06 Guire Patrick E Antimicrobial compositions and methods
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
RU2007140957A (ru) 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
AR054380A1 (es) 2005-06-09 2007-06-20 Schering Plough Ltd Control de parasitos en animales con derivados de n- ((feniloxi) fenil) -1,1,1-trifluorometansulfonamida y de n-(fenilsulfanil) fenil) -1,1,1-trifluorometansulfonamida
AU2006285613B2 (en) 2005-09-02 2011-11-17 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and harmful organism-controlling agent
EP1965645A2 (en) 2005-12-14 2008-09-10 E.I. Du Pont De Nemours And Company Isoxazolines for controlling invertebrate pests
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
PL1997813T3 (pl) 2006-03-10 2010-10-29 Nissan Chemical Ind Ltd Podstawiony związek izoksazolinowy i środek zwalczający szkodniki
DE102006015470A1 (de) 2006-03-31 2007-10-04 Bayer Cropscience Ag Substituierte Enaminocarbonylverbindungen
MX2008013468A (es) * 2006-04-20 2008-10-30 Hoffmann La Roche Nuevos derivados de diazepano.
WO2007125984A1 (ja) 2006-04-28 2007-11-08 Nihon Nohyaku Co., Ltd. イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法
JP2008044880A (ja) 2006-08-15 2008-02-28 Bayer Cropscience Ag 殺虫性イソオキサゾリン類
DE102006039283A1 (de) * 2006-08-22 2008-02-28 Henkel Kgaa Formfixierung faserhaltiger Materialien durch Polymere
EP1903038A1 (de) 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2683180A1 (en) 2007-04-10 2008-10-16 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
CA2683624A1 (en) 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW200900398A (en) 2007-05-31 2009-01-01 Du Pont 3-cyano-4-triazolyl phenylisoxazoline invertebrate pest control agents
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
SI2182945T1 (sl) 2007-06-27 2015-12-31 E.I. Du Pont De Nemours And Company Metoda za zatiranje škodljivcev pri živalih
CA2700598C (en) 2007-08-10 2012-11-20 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and pest control agent
EP2199287A4 (en) 2007-09-10 2011-04-27 Nissan Chemical Ind Ltd SUBSTITUTED ISOXAZOLINE COMPOUND AND AGENT FOR CONTROLLING PESTS
KR20100075996A (ko) 2007-10-03 2010-07-05 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충의 방제를 위한 나프탈렌 이속사졸린 화합물
WO2009051956A2 (en) 2007-10-16 2009-04-23 E. I. Du Pont De Nemours And Company Pyrazole-substituted isoxazoline insecticides
CN101284812A (zh) * 2008-06-05 2008-10-15 中山大学 他克林-阿魏酸杂联体,其制备方法及其药物组合物
US8809268B2 (en) 2008-10-29 2014-08-19 The Regents Of The University Of California Combination therapy to combat helminth resistance
US8007761B2 (en) 2008-12-24 2011-08-30 Praxair Technology, Inc. Carbon dioxide emission reduction method

Also Published As

Publication number Publication date
CN103189356B (zh) 2015-11-25
MX2013003635A (es) 2013-05-22
EP2621903B1 (en) 2017-03-01
WO2012041873A1 (en) 2012-04-05
JP2014500235A (ja) 2014-01-09
US20130196993A1 (en) 2013-08-01
US8877934B2 (en) 2014-11-04
JP5791725B2 (ja) 2015-10-07
RU2596185C2 (ru) 2016-08-27
CA2811369A1 (en) 2012-04-05
BR112013006030A2 (pt) 2016-06-07
CN103189356A (zh) 2013-07-03
PL2621903T3 (pl) 2017-08-31
BR112013006030B1 (pt) 2020-03-17
CN105294549A (zh) 2016-02-03
AU2011310592B2 (en) 2015-01-22
MX340985B (es) 2016-08-01
KR101916481B1 (ko) 2018-11-07
CN105294549B (zh) 2017-12-26
AU2011310592A1 (en) 2013-03-14
EP2621903A1 (en) 2013-08-07
KR20130139889A (ko) 2013-12-23
CA2811369C (en) 2019-09-03
NZ607580A (en) 2015-01-30
CO6710926A2 (es) 2013-07-15
HUE034042T2 (en) 2018-01-29
RU2013119681A (ru) 2014-11-10
ES2622881T3 (es) 2017-07-07

Similar Documents

Publication Publication Date Title
AR083200A1 (es) Compuestos de n-heteroarilo
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR082768A1 (es) Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR072249A1 (es) Inhibidores de amida hidrolasa de acido graso. usos. metodos.
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR064246A1 (es) Derivados de 5h-pirimido[5,4-d][2]benzazepinas inhibidores de la progresion mitotica,composiciones farmaceuticas que los contienen y usos como agentes anticancer.
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
AR082391A1 (es) Inhibidores biciclicos de acetil-coa y usos de los mismos
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR088218A1 (es) Compuestos heterociclicos utiles como inhibidores de pi3k
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal